{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:01:29Z","timestamp":1781020889582,"version":"3.54.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca PLC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eprac.2026.02.001","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T16:58:51Z","timestamp":1771865931000},"page":"947-954","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Sodium\u2013Glucose Co-Transporter-2 Inhibitors and Cardiovascular Effects in Kidney Transplant Recipients With Diabetes Mellitus"],"prefix":"10.1016","volume":"32","author":[{"given":"Idit","family":"Dotan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Polansky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idan","family":"Bergman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gida","family":"Ayada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Babich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Akirov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tali","family":"Steinmetz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6211-2073","authenticated-orcid":false,"given":"Talia","family":"Diker Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.02.001_bib1","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.001_bib2","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa1515920","article-title":"Empagliflozin and progression of kidney disease in type 2 diabetes","volume":"375","author":"Wanner","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.02.001_bib3","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.02.001_bib4","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.02.001_bib5","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","article-title":"Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records","volume":"11","author":"Xie","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.001_bib6","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00228-022-03327-w","article-title":"Exploring heterogeneities of cardiovascular efficacy and effectiveness of SGLT2 inhibitors in patients with type 2 diabetes: an umbrella review of evidence from randomized clinical trials versus real-world observational studies","volume":"78","author":"Seo","year":"2022","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.eprac.2026.02.001_bib7","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1161\/CIRCULATIONAHA.120.051824","article-title":"Effect of empagliflozin on cardiovascular and renal outcomes in patients with heart failure by baseline diabetes status: results from the EMPEROR-reduced trial","volume":"143","author":"Anker","year":"2021","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2026.02.001_bib8","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2026.02.001_bib9","doi-asserted-by":"crossref","first-page":"122","DOI":"10.2337\/dc19-1438","article-title":"Risk of rapid kidney function decline, all-cause mortality, and major cardiovascular events in nonalbuminuric chronic kidney disease in type 2 diabetes","volume":"43","author":"Buyadaa","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.001_bib10","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1053\/j.ajkd.2021.11.011","article-title":"Nonalbuminuric diabetic kidney disease and risk of all-cause mortality and cardiovascular and kidney outcomes in type 2 diabetes: findings from the Hong Kong diabetes biobank","volume":"80","author":"Jin","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.eprac.2026.02.001_bib11","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1161\/CIR.0000000000001186","article-title":"A synopsis of the evidence for the science and clinical management of cardiovascular-kidney-metabolic (CKM) syndrome: a scientific statement from the American Heart Association","volume":"148","author":"Ndumele","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2026.02.001_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2022.110200","article-title":"SGLT2 inhibitors reduce adverse kidney and cardiovascular events in patients with advanced diabetic kidney disease: a population-based propensity score-matched cohort study","volume":"195","author":"Chan","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eprac.2026.02.001_bib13","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.001_bib14","doi-asserted-by":"crossref","first-page":"3075","DOI":"10.2337\/dci22-0027","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and Kidney Disease: improving Global Outcomes (KDIGO)","volume":"45","author":"de Boer","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.001_bib15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/ndt\/gfz053","article-title":"Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies","volume":"34","author":"Rangaswami","year":"2019","journal-title":"Nephrol Dial Transpl"},{"key":"10.1016\/j.eprac.2026.02.001_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14718","article-title":"Sodium-glucose cotransporter 2 inhibitors for treatment of diabetes mellitus after kidney transplantation","volume":"36","author":"Lemke","year":"2022","journal-title":"Clin Transpl"},{"key":"10.1016\/j.eprac.2026.02.001_bib17","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.transproceed.2019.11.007","article-title":"Outcomes of SGLT2 inhibitors use in diabetic renal transplant patients","volume":"52","author":"AlKindi","year":"2020","journal-title":"Transpl Proc"},{"key":"10.1016\/j.eprac.2026.02.001_bib18","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1016\/j.transproceed.2019.05.023","article-title":"Use of empagliflozin in recipients of kidney transplant: a report of 8 cases","volume":"51","author":"Attallah","year":"2019","journal-title":"Transpl Proc"},{"key":"10.1016\/j.eprac.2026.02.001_bib19","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1159\/000501854","article-title":"Sodium-Glucose Cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus","volume":"44","author":"Mahling","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.eprac.2026.02.001_bib20","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1097\/TP.0000000000004228","article-title":"The efficacy and safety of SGLT2 inhibitor in diabetic kidney transplant recipients","volume":"106","author":"Lim","year":"2022","journal-title":"Transplantation"},{"key":"10.1016\/j.eprac.2026.02.001_bib21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/XCE.0000000000000246","article-title":"Successful use of the sodium-glucose co-transporter-2 inhibitor dapagliflozin in patients with renal transplant and diabetes: a case series and literature review","volume":"10","author":"Gul","year":"2021","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.02.001_bib22","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4103\/ijn.IJN_2_18","article-title":"Efficacy and safety of canagliflozin in kidney transplant patients","volume":"29","author":"Shah","year":"2019","journal-title":"Indian J Nephrol"},{"key":"10.1016\/j.eprac.2026.02.001_bib23","doi-asserted-by":"crossref","DOI":"10.1002\/edm2.185","article-title":"Early initiation of Sodium-Glucose Linked Transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients","volume":"4","author":"Song","year":"2021","journal-title":"Endocrinol Diabetes Metab"},{"key":"10.1016\/j.eprac.2026.02.001_bib24","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.2337\/dc17-0237","article-title":"Use of canagliflozin in kidney transplant recipients for the treatment of type 2 diabetes: a case series","volume":"40","author":"Rajasekeran","year":"2017","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.001_bib25","doi-asserted-by":"crossref","first-page":"2678","DOI":"10.1016\/j.transproceed.2021.08.042","article-title":"Institutional experience with new antidiabetic drugs in kidney transplant","volume":"53","author":"Yugueros Gonzalez","year":"2021","journal-title":"Transpl Proc"},{"key":"10.1016\/j.eprac.2026.02.001_bib26","doi-asserted-by":"crossref","DOI":"10.1097\/TXD.0000000000001228","article-title":"Safety and efficacy of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with pretransplant type 2 diabetes mellitus: a retrospective, single-center, inverse probability of treatment weighting analysis of 85 transplant patients","volume":"7","author":"Hisadome","year":"2021","journal-title":"Transpl Direct"},{"key":"10.1016\/j.eprac.2026.02.001_bib27","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1186\/s12882-022-02793-9","article-title":"Empagliflozin in kidney transplant recipients with chronic kidney disease G3a-4 and metabolic syndrome: five Japanese cases","volume":"23","author":"Miyazaki","year":"2022","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.eprac.2026.02.001_bib28","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s11255-023-03645-7","article-title":"The results of SGLT-2 inhibitors use in kidney transplantation: 1-year experiences from two centers","volume":"55","author":"Demir","year":"2023","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.eprac.2026.02.001_bib29","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ekir.2024.11.033","article-title":"Sodium-glucose Cotransporter-2 inhibitor in diabetic and nondiabetic renal transplant recipients","volume":"10","author":"Maigret","year":"2025","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.eprac.2026.02.001_bib30","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors in kidney transplant recipients with diabetes mellitus","volume":"51","author":"Diker Cohen","year":"2025","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.eprac.2026.02.001_bib31","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am J Transpl"},{"key":"10.1016\/j.eprac.2026.02.001_bib32","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.02.001_bib33","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1097\/TP.0000000000005496","article-title":"SGLT2 inhibitors and GLP-1 receptor agonists in kidney transplantation: a systematic review and meta-analysis","volume":"110","author":"Lee","year":"2025","journal-title":"Transplantation"},{"key":"10.1016\/j.eprac.2026.02.001_bib34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S2213-8587(20)30344-2","article-title":"Effects of empagliflozin on first and recurrent clinical events in patients with type 2 diabetes and atherosclerotic cardiovascular disease: a secondary analysis of the EMPA-REG OUTCOME trial","volume":"8","author":"McGuire","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2026.02.001_bib35","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54171-8","article-title":"The outcomes of SGLT-2 inhibitor utilization in diabetic kidney transplant recipients","volume":"15","author":"Sheu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.eprac.2026.02.001_bib36","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1016\/j.ekir.2024.05.022","article-title":"Cardioprotective effect of SGLT2 inhibitor in diabetic kidney transplant recipients: a multicenter propensity score matched study","volume":"9","author":"Lim","year":"2024","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.eprac.2026.02.001_bib37","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of Sodium Glucose Co-Transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"key":"10.1016\/j.eprac.2026.02.001_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/apha.14199","article-title":"Cardiovascular toxicities by calcineurin inhibitors: cellular mechanisms behind clinical manifestations","volume":"240","author":"Attachaipanich","year":"2024","journal-title":"Acta Physiol (Oxf)"},{"key":"10.1016\/j.eprac.2026.02.001_bib39","doi-asserted-by":"crossref","DOI":"10.1111\/ctr.14228","article-title":"Mtor inhibitors associated with higher cardiovascular adverse events-A large population database analysis","volume":"35","author":"Nguyen","year":"2021","journal-title":"Clin Transpl"},{"key":"10.1016\/j.eprac.2026.02.001_bib40","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000518535","article-title":"The Association of Pre-Kidney Transplant Dialysis Modality with de novo Posttransplant Heart Failure","volume":"11","author":"Lenihan","year":"2021","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.eprac.2026.02.001_bib41","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26007767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:27:09Z","timestamp":1781018829000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26007767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1530891X26007767"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.001","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sodium\u2013Glucose Co-Transporter-2 Inhibitors and Cardiovascular Effects in Kidney Transplant Recipients With Diabetes Mellitus","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.02.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}